Background: TG4023 is a modified vaccinia virus Ankara (MVA) containing the yeast-originated transgene FCU1, expressing cytosine deaminase and uracil phosphoribosyltransferase enzymes that transform the prodrug flucytosine (5-FC) into cytotoxic 5-fluorouracil (5-FU) and 5-fluorouridine-5 0 -monophosphate, respectively. This first-in-human study aimed to assess the maximum tolerated dose (MTD) of intratumoral (IT) TG4023 and the safety, feasibility, and proof-of-concept (PoC) of TG4023/5-FC combination to deliver high 5-FU concentrations in tumors.
Introduction
Primary and secondary liver tumors represent a significant burden. Hepatocellular carcinoma (HCC) is accounting for about 500 000 deaths per year, worldwide. The proportion of patients amenable to surgery remains at about 30% in developed countries. Radiofrequency ablation and transcatheter arterial chemoembolization (TACE) are routinely undertaken for nonresectable HCC. Since 5-year survival rate after TACE remains at 40%-70% and 5-year recurrence rate at over 70%, new therapeutic approaches are needed [1] .
In 2000, colorectal cancer (CRC) accounted for 2.4 million patients worldwide, 70% of whom developing liver metastasis. In 2004, about 374 400 new CRC cases and 203 700 deaths occurred in Europe and in 2005, 145 290 new cases and 56 290 deaths in the United States [2, 3] . Liver resection is the only curative option for only 20% of CRC patients with liver metastasis [4] . Palliative chemotherapy usually results in relapse or progression.
The anti-metabolite 5-FU has been for decades the only active agent to treat CRC and is still included in chemotherapy regimens for primary tumor and/or hepatic metastases [4] . However, systemic toxicity of 5-FU triggered the development of new approaches aiming to concentrate 5-FU in the tumor tissue. One of these approaches consists in using 5-FC, a non-cytotoxic prodrug of 5-FU and transforming it at the tumor site into 5-FU derivatives, implementing 'virus-directed enzyme-prodrug therapy' (VDEPT) [5] .
TG4023 is a recombinant non-replicative, hence nononcolytic, modified vaccinia virus Ankara (MVA), containing the FCU1 fusion gene originating from the yeast Saccharomyces cerevisiae FCY1 gene expressing the cytosine deaminase (CDase) and FUR1 gene expressing the uracil phosphoribosyltransferase (UPRTase) enzyme [6] . The bifunctional FCU1 enzyme generates 5-FU and 5-fluorouridine-5 0 -monophosphate from the prodrug 5-FC. Intratumoral (IT) injections of TG4023, combined with systemic administration of 5-FC, therefore represents a 5-FUbased in vivo cancer gene therapy. In vitro and in vivo experiments with mammalian cells that are devoid of CDase have shown that the FCU1 gene fulfills the features of a genuine and efficient prodrug gene therapy system. 5-FC and 5-FU penetrate tumor cells by passive diffusion allowing the toxic effect of locally produced 5-FU to affect neighboring non-transduced cancer cells (i.e. 'bystander effect'). In a human tumor-bearing immunodeficient mice study, the conversion of 5-FC to 5-FU in tumors after a single TG4023 IT injection in combination with oral 5-FC showed 5-FU peak concentration in tumors at 3-8 days and detection up to 14 days post-infection, indicating persisting FCU1 gene expression and/or FCU1 protein stability in tumors. Peak IT 5-FU level was similar to that reached with systemic 5-FU given at 20-fold the maximum tolerated dose (MTD), without detection of 5-FU in the serum and hence systemic toxicity [7] .
This first-in-human study tested the feasibility, safety, and efficacy of IT injections of TG4023 concomitantly with the systemic administration of 5-FC in patients with primary or secondary hepatic tumors.
Patients and methods

Study objectives and design
The primary objective of this open-label, multicenter, phase I study was to determine the MTD of percutaneous IT injections of TG4023, combined with systemic administration of 5 FC, in patients with primary or secondary hepatic tumors. Secondary objectives involved the assessment of tumor response and the demonstration of the proof-of-concept (PoC) of VDEPT by measuring 5-FU concentrations in both tumor biopsies and serum.
Patients were enrolled sequentially into dose-escalating cohorts (3 þ 3 design) (Figure 1 ). TG4023 MTD was determined according to the occurrence of dose-limiting toxicities (DLTs) in two or more of six patients exposed to the next higher dose level defined as a grade 3 or 4 adverse events (AEs), considered related to treatment.
An at least 1-week safety interval was applied between TG4023 injection of consecutive patients in a given cohort and a 6-week interval was applied between consecutive cohorts. The decision to initiate a new cohort with the next higher dose of TG4023 was agreed upon by an Independent Data Safety Monitoring Board (IDSMB) after analysis of the safety results of the completed cohort.
Patients
Eligible patients were !18 years old, with advanced progressing disease without any standard of care options, and presenting with one nonresectable target tumor in the liver measuring 2-5 cm, an Eastern Cooperative Oncology Group performance status 2, and a life expectancy of !3 months. Key laboratory parameters included international normalized ratio 2; ALT, aspartate aminotransferase (AST), and alkaline phosphatase 5 Â ULN; total bilirubin 3 Â ULN. A wash-out period of at least 4 weeks from the last chemotherapy/targeted therapy was mandatory before TG4023 administration. Patients were excluded if they had Child-Pugh stage C hepatic insufficiency, ascites or brain metastases. Eligible patients were sequentially included in four participating centers in France.
Treatment plan
The volume of TG4023 suspension was adjusted to one-eighth of tumor volume, using a dedicated diluent. TG4023 was then injected percutaneously into one single hepatic lesion, through ultrasound or computerized tomography (CT) imaging guidance. On day 1 (D1), doses injected up to the determination of the MTD included 1 Â 10 7 , 1 Â 10 8 , and 4 Â 10 8 plaque forming units (p.f.u.). Starting the day after TG4023 injection (D2) and for 14 days, patients were administered 5-FC at the 50 mg/ kg q.i.d. dose p.o. or i.v. followed by p.o., owing to its excellent oral bioavailability [8] . Plasma 5-FC levels were monitored at steady state (D4) and dose was proportionally adjusted to maintain 5-FC levels under 100 mg/l from D8 onwards, if needed. After all dosing was completed, patients were followed for 4 weeks for post-treatment safety and further for survival. A second administration of TG4023 and 5-FC was allowed upon investigator's judgment on patient benefit.
The study was conducted in conformance with the principles of the 1996 Declaration of Helsinki and Good Clinical Practice, outlined in 21 Code of Federal Regulations, subchapter D, part 312. The protocol and informed consent were reviewed and approved by French Health Figure 1 . Study schema and determination of maximal tolerated dose. Patients were enrolled in the study based on a 3 þ 3 dose-escalation design. A total of 16 were enrolled and treated with TG4023 and 5-FC. p.f.u., plaque forming units ; MTD, maximum tolerated dose; DLT, dose limiting toxicity; DSMB, data safety monitoring board; i.v., intravenous; p.o., oral; AST, aspartate aminotransferase.
Authorities and a central ethics committee (CPP). Before any studyrelated procedure, patients provided written informed consent.
Safety
Safety analyses included all enrolled patients with at least one dose of TG4023 or 5-FC and included all events through 4 weeks post-treatment. AEs, serious AEs (SAEs), deaths due to AEs, AEs leading to discontinuation, adverse drug reactions, and laboratory abnormalities were graded according to the Common Terminology Criteria for AEs (CTCAE) version 3.0. The IDSMB also assessed the safety of participating patients on an ongoing basis.
Tumor response
Tumor response was a secondary objective of the study and was assessed by tumor imaging at baseline and 6 weeks after IT injection of TG4023, using RECIST [9] , of the injected lesion(s), and, if appropriate, of any distant lesion(s). The best overall response in the liver including nontarget hepatic lesions was summarized by treatment cohort and overall.
5-FU concentrations in plasma and tumor tissue
Concentrations of the prodrug 5-FC, 5-FU, and alpha-fluoro-betaalanine (F-BAL, the ultimate 5-FU catabolite) were evaluated at specified time points through day 15, using liquid chromatography-mass spectrometry tandem (Laboratoire de Ciblage Thérapeutique en Cancérologie, Centre Hospitalier Lyon Sud, France). Additionally, 5-FU concentrations were measured in available tumor biopsy at day 8 to establish the PoC of converting 5-FC into 5-FU in the tumor.
Statistical analyses
All safety data through 4 weeks post-treatment were summarized descriptively.
Results
Patient characteristics
The patients' baseline characteristics were similar across the three cohorts ( Table 1) . The majority of patients was male (13/16), aged 33-85, and had metastases of CRC (13/16). Sixteen patients eligible for the trial were injected with TG4023 in one tumor. Baseline total bilirubin was normal for 13/16 patients, within protocol specifications for two and above for one (3.5 ULN). Six, three, and seven patients were enrolled into cohorts 1, 2, and 3, respectively. As all three patients of cohort 1 presented a moderate and transient transaminases increase, although not qualifying for a DLT, IDSMB advised to include three more patients, in whom the deviation was not repeated. Based on the occurrence of one DLT in cohort 3 (grade 3 cytolysis), this cohort was also duplicated; two patients screened at a time were included and treated in this cohort, which included seven patients ( Figure 1 ).
Safety
Dose-limiting toxicity. A grade-3 cytolysis that met the definition of a DLT occurred in one patient in the highest dose cohort. After the TG4023 injection and the initiation of 5-FC treatment, the patient presented a sudden, increase (day 15) in transaminases, regressing from day 22 onwards and combined with a rapid disease progression. Alkaline phosphatase levels rose to 723 IU/l on day 15 and remained high, with a significant concomitant increase (grade 3-4) in bilirubin (252 mmol/l at the end of the study). The initial transitory cholestatic effect was considered most likely linked to the IT injection and tumor acute inflammation and swelling. No DLT was observed in either duplicated cohort 1 or cohort 2 or duplicated cohort 3, resulting in the MTD to not be reached at highest dose level.
Adverse events. Overall, the most frequently reported AEs included pyrexia, asthenia, vomiting, and decreased appetite ( Table 2 ). The only AE that suggested a dose-response was pyrexia. Among the 162 observed AEs, 35 were of grade 3 or higher; 15 AEs observed in 13 patients were considered by investigators related to treatment with TG4023: all but one (grade 3 ALT increase, DLT) were grade 1-2: pyrexia (10 patients), asthenia (five patients), injection site pain (two patients), anemia (two patients), and miscellaneous (one patient each). Overall, 10 patients experienced 11 SAEs, of which one, pyrexia (grade 1), was considered related to TG4023 and 5-FC. Three SAEs resulted in death, none considered related to TG4023.
Laboratory abnormalities. Supplementary Table S1 , available at Annals of Oncology online, provides a shift table of all laboratory abnormalities of !grade 3 on treatment. Few patients experienced grade 3 or 4 hematologic abnormalities and increases in AST, alkaline phosphatase, and bilirubin were observed across all cohorts; grade-3 ALT increases were observed in the lowest and highest dose cohorts. Generally, the increases observed in alkaline phosphatase were regressive peaks, concomitant to increases in bilirubin and C-reactive protein (data not shown); these abnormalities are likely related to inflammation resulting from the physical injection of the hepatic tumor and local reaction to the virus, expression of the transgene and cytotoxic effect of 5-FU. Although tumor markers increased across all dose cohorts following treatment discontinuation, carcinoembryonic antigen (CEA) levels increased to a much greater extent in cohorts 1 and 2 (data not shown). Notably, a CRC patient in cohort 2 experienced a threefold decrease in both CEA and CA 19-9.
Tumor response. Tumor response was evaluated 6 weeks after TG4023 injection. The overall tumor response rate (including target and non-target hepatic lesions) was similar across the three dose cohorts with 8 of 16 patients showing stable disease (50%) and 7 of 16 showing progressive disease (43%). However, all three cohorts showed a median percent increase from baseline of the sum of diameters of target lesions (range 0%-4%).
5-FC, 5-FU, F-BAL concentrations.
The concentrations of 5-FC, 5-FU, and F-BAL were measured in plasma at various time points on study. Throughout the study, from day 2, there were measurable, low concentrations of 5-FU and F-BAL in the plasma, supporting conversion of the prodrug 5-FC to 5-FU (data not shown). For two patients, sufficient available tumor tissue on day 8 allowed the comparison of the concentrations of 5-FU in plasma and in tumor tissue that were 3.60 and 0.44 ng/ml in plasma and 78.0 and 36.8 ng/g of tumor tissue, for each patient, respectively. Resulting mean 5-FU concentrations in plasma were 1.9 6 2.6 ng/ml and 56 6 30 ng/g in tumors. TG4023-specific humoral responses: anti-FCU1 antibodies. Total anti-FCU1 circulating immunoglobulins were assessed in the serum using enzyme-linked immunosorbent assay. At baseline, all patients were seronegative for total anti-FCU1 antibodies. Overall, 3 of 16 patients (19%; one patient from each cohort) had an increase in anti-FCU1 antibody levels following injection of TG4023.
Discussion
Suicide gene therapy or gene-or here virus-directed enzyme prodrug therapy has been considered an attractive strategy for targeted therapy of cancer. This technology allows toxic drugs to be only produced in tumor cells while yielding minimal exposure and consecutive toxicity. It involves the transduction of cancer cells by a gene, whose expression is producing an enzyme catalyzing the conversion of a non-toxic prodrug into the cytotoxic agent. Also important in the overall antitumor effect is the occurrence of a 'bystander' effect, which affects neighboring cancer cells, not transduced by the suicide gene. Many enzyme/prodrug systems have been investigated so far; optimization of the technology involved the use of a viral gene carrier, the choice of a gene able to express a potent enzyme, like CDase/UPRTase, and the selection of a vector with enhanced infectivity and tropism for cancer cells and gene harboring capacity like vaccinia viruses [10, 11] . In this study, we report for the first time in human the PoC of VDEPT using IT delivery of the vaccinia vector TG4023 and systemic administration of 5-FC. Safety, feasibility, and preliminary efficacy of VDEPT were also evaluated, showing promising results. VDEPT using FCU1 gene engineering delivered 5-FU directly to cancer cells, thus minimizing the systemic toxicity of 5-FU. Moreover, the 5-FU concentrations reached in biopsied tumors were comparable to the levels observed in patients treated with 5-FU-based regimens [11] , without related toxicity. The study demonstrated the feasibility of percutaneous IT injections using ultrasound or CT-guidance. TG4023 in combination with the prodrug 5-FC was well tolerated in this patient population at all dose levels and the MTD was determined to be the highest dose level of 4 Â 10 8 p.f.u., based on an observed DLT in a single patient at that dose. This patient experienced severe cytolysis and rapid disease progression. However, further enrollment at this dose level demonstrated safety and tolerability without significant increases in ALT/AST. Preliminary efficacy was measured by tumor imaging and RECIST at 6 weeks. Although no response was observed, 8 of 16 patients had stable disease and notably a CRC patient who received a dose of 1 Â 10 8 p.f.u. of TG4023 experienced a threefold decrease in CEA and CA 19-9 tumor markers. The limitations of VDEPT are related to the IT approach, to drug storage (À20 C) and preparation, which involves volume adjustment to tumor; however, given the validation of the PoC of the FCU1/ 5FC approach, future developments are now ongoing. The key issue of targeting the tumor might be circumvented by alternative viral vectorization using oncolytic virus strains. Indeed, the systemic administration of the combination of an oncolytic virus harboring the FCU1 transgene with 5-FC is an exciting perspective that might benefit to patients who have failed currently approved treatments with the perspective of simultaneously treating all cancer sites [12] .
This trial demonstrated the feasibility and safety of the percutaneous injection in liver tumors of a genetically modified nonreplicative vaccinia virus; moreover, was established the PoC of a targeted molecular chemotherapy combining a targeted vector infection of tumor cells and the intratumor expression of a yeast transgene, FCU1, generating cytotoxic 5-FU from the noncytotoxic prodrug 5-FC. Beyond the PoC demonstrated in this study, VDEPT as TG4023 might be a treatment option challenging locoregional delivery of anticancer therapy such as chemoembolization for liver cancer or even intra-arterial chemotherapy. Conversely, it is probably less efficient than thermal ablation (either radiofrequency or cryoablation) that is more adapted to a very limited number of targets. Indeed, using viral vectors loaded with FCU1 transgenes would be of interest in tumors where 5-FU is expected to be active, including CRC and perhaps pancreas and liver cancer, because of high intratumor 5-FU concentrations allowed by this technology. Moreover, the systemic administration of replicative design of oncolytic viruses expressing the FCU1 transgene may overcome the drawback of local/locoregional delivery and combine both the targeted viral toxicity of the vector and the pharmaceutical advantages of the transgene that have been demonstrated in this study.
